Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Infectious Diseases and Therapy

Volumn 4, Issue 4, 2015, Pages 391-415

  Bergen, Phillip J ^b   Bulman, Zackery P ^a   Landersdorfer, Cornelia B ^b   Smith, Nicholas ^a   Lenhard, Justin R ^a   Bulitta, Jürgen B ^c   Nation, Roger L ^b   Li, Jian ^b   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Colistin; Colistin methanesulfonate; Combination; Pharmacodynamic; Polymyxin B; Polymyxins

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CHLORAMPHENICOL; COLISTIMETHATE; COLISTIN; DAPTOMYCIN; DORIPENEM; FOSFOMYCIN; FUSIDIC ACID; GLYCOPEPTIDE; LINEZOLID; PIPERACILLIN; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; BACTERICIDAL ACTIVITY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE MODEL; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA MARCESCENS; SYSTEMATIC REVIEW (TOPIC);

EID: 84977110729     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-015-0093-7     Document Type: Review

References (133)

1. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953–8.
2. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857–68.
3. Yow EM, Moyer JH. Toxicity of polymyxin B. II. Human studies with particular reference to evaluation of renal function. AMA Arch Intern Med. 1953;92(2):248–57.
4. WHO. Antimicrobial resistance: global report on surveillance. 2014 April 2014. Report No. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 25 July 2015.
5. Walker B, Barrett S, Polasky S, Galaz V, Folke C, Engstrom G, et al. Environment. Looming global-scale failures and missing institutions. Science. 2009;325(5946):1345–6.
6. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, et al. 10 × ‘20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–94.
7. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94 (Epub 2011/05/11. eng).
8. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–31.
9. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241–9 (Epub 2012/05/23. eng).
10. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003;52(6):987–92.
11. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54(9):3783–9 (Epub 2010/06/30. eng).
12. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47(3):905–9.
13. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;59(3):473–7 (Epub 2007/02/10. eng).
14. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(6):1311–8 (Epub 2008/10/17. eng).
15. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(9):3624–30.
16. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007;51(9):3413–5 (Epub 2007/07/11. eng).
17. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011;55(11):5134–42 (Epub 2011/08/31. eng).
18. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(12):5685–95 (Epub 2011/09/14. eng).
19. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D’Hondt RE, et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother. 2010;54(5):2051–62 (Epub 2010/03/10. eng).
20. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61(3):636–42.
21. Deris ZZ, Yu HH, Davis K, Soon RL, Jacob J, Ku CK, et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56(10):5103–12 (Epub 2012/07/18. eng).
22. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738–45.
23. Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother. 2015;70(5):1434–42 (Epub 2015/02/26. eng).
24. Abdul Rahim N, Cheah SE, Johnson MD, Yu H, Sidjabat HE, Boyce J, et al. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics-polymyxin B and chloramphenicol. J Antimicrob Chemother. 2015;70(9):2589–97.
25. Choi MJ, Ko KS. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother. 2014;69(1):275–7.
26. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610 (Epub 2009/10/14. eng).
27. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;1(43 Suppl 2):S95–9 (Epub 2006/08/09. eng).
28. Herrmann G, Yang L, Wu H, Song Z, Wang H, Hoiby N, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010;202(10):1585–92 (Epub 2010/10/15. eng).
29. Bulitta JB, Li J, Poudyal A, Yu HH, Owen RJ, Tsuji BT, et al. Quantifying synergy of colistin combinations against MDR Gram-negatives by mechanism-based models (abstract A1-573, p41). In: Abstracts of the 49th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco: American Society for Microbiology, September 12–15; 2009.
30. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother. 2011;66(9):2070–4 (Epub 2011/07/01. eng).
31. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in acinetobacter species isolated from patients in Kuwait hospitals. J Chemother. 2011;23(1):13–6 (Epub 2011/04/13. eng).
32. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis. 2011;53(4):373–6 (Epub 2011/08/04. eng).
33. Lee JY, Song JH, Ko KS. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb Drug Resist. 2011;17(2):299–304 (Epub 2011/03/09. eng).
34. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;55(2):593–9 (Epub 2010/12/01. eng).
35. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816–27 (Epub 2008/10/11. eng).
36. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005;49(8):3136–46.
37. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE. 2012;7(12):e52349.
38. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, Espejo-Gutierrez de Tena E, Artero-Gonzalez ML, Corcia-Palomo Y, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59(3):225–31.
39. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58(2):851–8.
40. Morelli P, Ferrario A, Tordato F, Piazza A, Casari E. Successful treatment of post-neurosurgical multidrug-resistant Pseudomonas aeruginosa meningo-encephalitis with combination therapy of colistin, rifampicin and doripenem. J Antimicrob Chemother. 2014;69(3):857–9.
41. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.
42. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57(6):2900–1.
43. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22 (Epub 2012/09/08. eng).
44. Batirel A, Balkan, II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311–22.
45. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–9.
46. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601 (Epub 2014/07/02. eng).
47. Chua NG, Zhou YP, Tan TT, Lingegowda PB, Lee W, Lim TP, et al. Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. J Infect. 2015;70(3):309–11 (Epub 2014/10/12. eng).
48. Dan JM, Mendler MH, Hemming AW, Aslam S. High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient. BMJ Case Rep. 2014.
49. Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–204 (Epub 2015/03/21. eng).
50. Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(5):476–85 (Epub 2015/05/20. eng).
51. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74(3):213–23 (Epub 2012/09/11. eng).
52. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011;11(5):464–9 (Epub 2011/08/13. eng).
53. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40(3):677–83 (Epub 1996/03/01. eng).
54. Wootton M, Hedges AJ, Bowker KE, Holt HA, Reeves DS, MacGowan AP. A critical assessment of the agar dilution chequerboard technique for studying in vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother. 1995;35(5):569–76.
55. Norden CW, Wentzel H, Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis. 1979;140(4):629–33 (Epub 1979/10/01. eng).
56. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;60(2):421–3 (Epub 2007/06/02. eng).
57. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45(1):8–18 (Epub 2014/12/04. eng).
58. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
59. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104–11.
60. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63(3):534–42 (Epub 2009/01/17. Eng).
61. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007;30(6):537–40 (Epub 2007/09/14. eng).
62. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis. 2011;11:109 (Epub 2011/04/28. eng).
63. Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother. 2004;16(3):282–7.
64. Attridge RT, Carden MF, Padilla S, Nathisuwan S, Burgess DS. Colistin and rifampicin alone and in combination against multidrug-resistant Acinetobacter baumannii using an in vitro PK-PD model (abstract C1-1053, p69). In: Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC: American Society for Microbiology, October 25–28; 2008.
65. Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M, et al. Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase producing Gram-negative bacteria. J Chemother. 2014;26(4):211–6.
66. Tangden T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58(3):1757–62.
67. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69(7):1856–65.
68. Betts JW, Phee LM, Woodford N, Wareham DW. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2014;33(9):1565–72.
69. Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother. 2007;51(6):2005–10.
70. Lin KH, Chuang YC, Lee SH, Yu WL. In vitro synergistic antimicrobial effect of imipenem and colistin against an isolate of multidrug-resistant Enterobacter cloacae. J Microbiol Immunol Infect. 2010;43(4):317–22 (Epub 2010/08/07. eng).
71. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother. 2008;52(1):333–6.
72. Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2010;67(2):191–7 (Epub 2010/03/27. eng).
73. Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011;70(3):380–6 (Epub 2011/05/12. eng).
74. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother. 2009;53(5):2133–5 (Epub 2009/03/05. eng).
75. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against Multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother. 2010;54(6):2732–4 (Epub 2010/04/07. eng).
76. Srisupha-olarn W, Burgess DS. Activity of meropenem and colistin alone and in combination against multidrug-resistant Acinetobacter baumannii in a pharmacokinetic-pharmacodynamic model (abstract E-1591, p125). In: Abstracts of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston: American Society for Microbiology, September 12–15; 2010.
77. Lee GC, Burgess DS. Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2013;5(2):97–100.
78. Principe L, Capone A, Mazzarelli A, D’Arezzo S, Bordi E, Di Caro A, et al. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist. 2013;19(5):407–14.
79. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O’Hara JA, Doi Y, et al. In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother. 2014;58(2):1195–9.
80. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother. 2013;57(11):5258–65.
81. Lora-Tamayo J, Murillo O, Bergen PJ, Nation RL, Poudyal A, Luo X, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother. 2014;69(9):2434–42.
82. Tang HJ, Ku YH, Lee MF. In vitro activity of imipenem and colistin against a carbapenem-resistant Klebsiella pneumoniae isolate coproducing SHV-31, CMY-2, and DHA-1. 2015;2015:568079. Biomed Res Int. 2015; 2015, Article ID 568079.
83. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, et al. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother. 2013;57(5):2147–53 (Epub 2013/03/06. eng).
84. Sun HY, Shields RK, Cacciarelli TV, Muder RR, Singh N. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient. Transpl Infect Dis. 2010;12(6):555–60 (Epub 2010/07/16. eng).
85. Padilla S, Carden MF, Attridge RT, Burgess DS. In-vitro activity of colistin, amikacin and in combination against multi-drug resistant Acinetobacter baumannii in a pharmacodynamic-pharmacokinetic model model. 4th Annual Louis C Littlefield Celebrating Pharmacy Research Excellence Day in Professional, Graduate and Postgraduate Programs. Austin: University of Texas, April 17 2008.
86. Corvec S, Tafin UF, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57(3):1421–7.
87. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(12):5316–22.
88. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011;66(5):1047–51 (Epub 2011/03/12. eng).
89. Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56(9):4856–61.
90. Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activity of tigecycline/colistin combination therapies against carbapenem resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(6):3541–6.
91. Liu B, Liu Y, Di X, Zhang X, Wang R, Bai Y, et al. Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii. Rev Soc Bras Med Trop. 2014;47(4):451–6 (Epub 2014/09/18. eng).
92. Percin D, Akyol S, Kalin G. In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii. GMS Hyg Infect Control. 2014;9(2):Doc14 (Epub 2014/08/26. eng).
93. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37(3):244–7.
94. Albur M, Noel A, Bowker K, MacGowan A. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56(6):3441–3.
95. Demiraslan H, Dinc G, Ahmed SS, Elmali F, Metan G, Alp E, et al. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. J Chemother. 2014;26(5):276–81
96. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2013;57(12):6028–33.
97. Yilmaz EM, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40(4):332–6.
98. Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55(5):2395–7 (Epub 2011/02/16. eng).
99. Di X, Wang R, Liu B, Zhang X, Ni W, Wang J, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. J Antibiot (Tokyo). 2015;68(9):551–5.
100. Safarika A, Galani I, Pistiki A, Giamarellos-Bourboulis EJ. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2015;34(2):317–23 (Epub 2014/09/07. eng).
101. Yang H, Chen G, Hu L, Liu Y, Cheng J, Li H, et al. In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2015;45(2):188–91 (Epub 2014/12/03. eng).
102. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2014;43(4):370–4.
103. Phee L, Hornsey M, Wareham DW. In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin Microbiol Infect Dis. 2013;32(10):1291–4 (Epub 2013/04/24. eng).
104. Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and fusidic acid: a novel potent synergistic combination for the treatment of multi-drug resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2015;59(8):4544–50.
105. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–52 (Epub 2011/03/01. eng).
106. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect. 2002;8(3):144–53 (Epub 2002/05/16. eng).
107. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1998;42(6):793–802 (Epub 1999/03/03. eng).
108. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53(10):4069–79.
109. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;6:CD007022.
110. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333–9 (Epub 2010/06/19. eng).
111. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother. 2009;53:3430–6 (Epub 2009/05/13. Eng).
112. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143–51 (Epub 2008/03/18. eng).
113. Mah TF, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;9(1):34–9 (Epub 2001/02/13. eng).
114. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros. 2011;10(5):357–65.
115. Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, Jimenez-Mejias ME, Garcia-Curiel A, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(3):1165–72 (Epub 2010/01/06. eng).
116. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004;54(6):1085–91 (Epub 2004/11/18. eng).
117. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents. 2007;29(1):51–5 (Epub 2006/12/26. eng).
118. Cirioni O, Ghiselli R, Orlando F, Silvestri C, Mocchegiani F, Rocchi M, et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med. 2007;35(7):1717–23 (Epub 2007/04/25. eng).
119. Giacometti A, Cirioni O, Ghiselli R, Orlando F, Mocchegiani F, D’Amato G, et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother. 2003;15(2):129–33 (Epub 2003/06/12. eng).
120. Dinc G, Demiraslan H, Elmali F, Ahmed SS, Alp E, Doganay M. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol. 2015;38(1):67–73 (Epub 2015/03/06. eng).
121. Zak O, O’Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother. 1991;35(8):1527–31 (Epub 1991/08/01. eng).
122. Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, et al. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis. Chemotherapy. 2014;59(5):325–9.
123. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55(7):3534–7.
124. Hornsey M, Phee L, Longshaw C, Wareham DW. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2013;41(3):285–7.
125. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–6 (Epub 2012/03/17. eng).
126. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–9 (Epub 2009/12/17. eng).
127. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–7 (Epub 2010/08/06. eng).
128. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–13.
129. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–803.
130. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–50.
131. Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2013;57(11):5394–7.
132. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37(11):e154–60 (Epub 2003/11/14. eng).
133. Furtado GHC, d’Azevedo PA, Santos AF, Gales AC, Pignatari ACC, Medeiros EAS. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30(4):315–9.